Eli Lilly, Novartis and Pfizer have found a new home for the tech they created to improve ClinicalTrials.gov. The group is giving what it has achieved to date to TrialReach, a tech company developing a patient-focused clinical trial discovery platform.
London startup TrialReach hauled in $13.5 million in Series B cash, funds that will help expand its technology designed to connect patients with their ideal clinical trials.
TrialReach raised $13.5 million in a Series B round to scale up its clinical trial discovery platform. The system is designed to accelerate enrollment into clinical research by matching patients to appropriate trials.
Sponsors and contract research outfits know all too well the pain of finding qualified patients for clinical research, as delays in recruitment can stall a program's development progress....